Last reviewed · How we verify

NCT03338543

PENS or TENS for Pain in Liver Cancer

Completed NA Last updated 12 September 2019
What this trial tests

NA trial testing PENS in Pain in 36 participants. Completed in 30 August 2019.

Timeline
1 November 2017
Primary endpoint
30 April 2018
30 August 2019

Quick facts

Lead sponsorFuda Cancer Hospital, Guangzhou
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment36
Start date1 November 2017
Primary completion30 April 2018
Estimated completion30 August 2019
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Fuda Cancer Hospital, Guangzhou

Who can join

Adults 18 to 70, any sex, with Pain or Cancer Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effect of percutaneous electrical nerve stimulation (PENS) and transcutaneous nerve stimulation (TENS) for pain relieving in patients with liver cancer. Patients will randomly allocated into PENS group, Tens group and control group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of PENS

Trials testing the same drug.

Other recruiting trials for Pain

Currently open trials in the same condition.

Other Fuda Cancer Hospital, Guangzhou trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03338543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing